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Ultrasonography of salivary glands in primary Sjo¨gren’s syndrome:
a comparison with contrast sialography and scintigraphy
F. Salaffi1, M. Carotti2, A. Iagnocco3, F. Luccioli4, R. Ramonda5, E. Sabatini3, M. De Nicola6,
M. Maggi6, R. Priori3, G. Valesini3, R. Gerli4, L. Punzi5, G. M. Giuseppetti2, U. Salvolini6
and W. Grassi1
Objective. To compare ultrasonography (US) of salivary glands with contrast sialography and scintigraphy, in order to evaluate the diagnostic
value of this method in primary SS (pSS).
Methods. The diagnostic value of parotid gland US was studied in 77 patients with pSS (male/female ratio 3/74; mean age 54 yrs) and in 79
with sicca symptoms but without SS. The two groups were matched for sex and age. Imaging findings of US were graded using an
ultrasonographic score ranging from 0 to 16, which was obtained by the sum of the scores for each parotid and submandibular gland.
The sialographic and scintigraphic patterns were classified in four different stages. The area under receiver operating characteristic curve
(AUC-ROC) was employed to evaluate the screening method’s performance.
Results. Of the 77 patients with pSS, 66 had abnormal US findings. Mean US score in pSS patients was 9.0 (range from 3 to 16). Subjects
without confirmed pSS had the mean US score 3.9 (range from 0 to 9) (P< 0.0001). Results of sialography showed that 59 pSS patients had
abnormal findings at Stage 1 (n¼ 4), Stage 2 (n¼ 8), Stage 3 (n¼ 33) or Stage 4 (n¼ 14), and 58 patients had abnormal scintigraphic findings
at Stage 1 (n¼ 11), Stage 2 (n¼ 18), Stage 3 (n¼ 25) or Stage 4 (n¼ 4). Through ROC curves US arose as the best performer
(AUC¼ 0.863 0.030), followed by sialography (AUC¼ 0.804 0.035) and by salivary gland scintigraphy (AUC¼ 0.783 0.037). The
difference between AUC-ROC curve of salivary gland US and scintigraphy was significant (P¼ 0.034). Setting the cut-off score >6 US
resulted in the best ratio of sensitivity (75.3%) to specificity (83.5%), with a likelihood ratio of 4.58. If a threshold >8.0 was applied the test
gained specificity, at the cost of a serious loss of sensitivity (sensitivity 54.5%, specificity 97.5%, likelihood ratio 21.5).
Conclusions. Salivary gland US is a useful method in visualizing glandular structural changes in patients suspected of having pSS and it may
represent a good option as a first-line imaging tool in the diagnostics of the disease.
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Introduction
Sjo¨gren’s syndrome (SS), also known as ‘autoimmune exocrino-
pathy’ [1] or ‘autoimmune epithelitis’ [2], is a chronic inflamma-
tory disease that primarily affects females. It is characterized
clinically by dry eyes (keratoconjunctivitis sicca) and dry mouth
(xerostomia) and histologically by lymphocytic infiltration
and destruction of the salivary and lachrymal glands [2]. The
term primary SS (pSS) applies to those patients in whom SS
is not associated with other autoimmune diseases [2]. In spite of
the recently published classification criteria proposed by the
American–European Consensus group in 2002 (which also serve
as diagnostic criteria) [3], the evaluation of salivary gland involve-
ment in SS is still a matter of debate. In addition to standard tests
for assessment of salivary gland involvement, namely the unstimu-
lated salivary flow test, salivary gland scintigraphy and contrast
sialography, other methods have been studied such as ultra-
sonography (US), MRI, CT [4–6]. These diagnostic tools have
widely replaced conventional invasive examinations in scientific
research as well as in clinical practice. Among them, US of the
major salivary glands seem the most attractive as a non-invasive,
inexpensive and non-irradiating investigation. According to avail-
able data, it seems to yield quite definitive information about the
morphological changes of salivary glands in SS. In recent years,
also, colour Doppler US has been used to evaluate the vascular
anatomy of the salivary glands and to analyse the physiological
changes in blood flow that occur during salivary stimulation in the
diseased glands of SS patients [7–13].
The purpose of this multi-centre cross-sectional study was to
examine salivary glands in pSS patients and in symptomatic
controls by using modern US equipment in order to determine
whether US can take the place of contrast sialography or scin-
tigraphy as an alternative technique for the assessment of salivary
gland involvement in SS.
Materials and methods
Patients
Patients who had been referred to the Department of
Rheumatology of the Universita` Politecnica delle Marche, to the
Department of Rheumatology of Sapienza University of Rome,
to the Department of Rheumatology of the University of Padova
and to the Rheumatology Units of the University of Perugia for
symptoms suggesting sicca syndrome were evaluated using the
proposed recently criteria revised by the American–European
Consensus Group (AECG) [3]. Patients who had been treated
during the last 12 months with either immunosuppressive agents
or other drugs known potentially to cause a reduction in salivary
and lachrymal secretions were not included in the study. Only
those patients in whom a minor salivary glands biopsy was
available were selected for inclusion in the present research. All
subjects gave informed consent to participate in the study, which
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was performed according to the criteria of the Helsinki
Declaration and the study was approved by the institutional
review boards for human research.
Clinical and histopathological evaluation
A complete SS work-up was available in all patients, including
data on whole and gland-specific salivary involvement, level of
subjective complaints and disease duration. Disease duration was
defined as the time from first complaints related to oral dryness up
to the US evaluation stage. All patients were asked to come to
four Departments of Rheumatology between 9 a.m. and 11 a.m.,
having fasted and not brushed their teeth, rinsed their mouth or
smoked tobacco for at least 1 h before the examination took place.
Six questions to assess both ocular and oral involvement were
given to each patient [14]. Information on related treatment was
collected at the same time. Besides the questionnaire, all patients
were subjected to a Schirmer-I test, Saxon test and serological
tests. In these 156 subjects, minor salivary glands (MSGs) were
excised through the mucosa of the lower lip within 3 weeks
after the imaging studies. A minimum of four minor salivary
glands per biopsy was obtained. Focus score was determined on
the basis of number of inflammatory cell aggregates containing
>50 lymphocytes/4mm2 of salivary gland tissue [15]. A diagnosis
of SS syndrome was made if at least one focus (focal sialadenitis)
was found (Grades 3 and 4) [3]. The MSG biopsy specimens were
examined separately by two observers who were unaware of the
clinical findings. The differences between the two sets of results
were negligible. The inter-observer agreement (k-value) in the
evaluation of the MSG biopsy specimens, evaluated in a sample
of 31 subjects, was 0.783.
Laboratory investigations
An indirect immunofluorescence procedure using Hep-2 cell
substrates was employed to detect the presence and titre of
ANA. The serum levels of RF were evaluated by laser nephe-
lometry. ANA titres >1 : 160 and RF levels >40 IU/ml in at
least two consecutive determinations were considered positive.
Anti-SSA/Ro and anti-SSB/La were detected by counter-
immunoelectrophoresis.
Ultrasonographic examination
On the same day of the clinical examination, all patients under-
went a US assessment by a rheumatologist or radiologist
experienced in US and blinded to the results of the clinical
assessment. US examinations were performed using an
TECHNOS MP (ESAOTE Biomedica, Genoa, Italy) equipped
with two broadband linear probes (7.5–10.0MHz). Each patient
was scanned in the supine position with the neck hyperextended
and the head turned a little to the opposite side. The parotid
glands were examined in both axial and coronal planes and the
submandibular glands only in coronal ones. The following US
parameters were recorded: parenchymal homogeneity, echogeni-
city, size of the glands and posterior glandular border. Each of
these parameters was scored according to previously described
scoring system [13]. A sonographic score, ranging from 0 to 16,
was obtained from the sum of the scores (0–4) for each parotid
and submandibular gland. A US pattern was considered abnormal
if both parotids or both submandibular glands exhibited a
minimum score of 1. The characteristic sonographic pictures on
score 3 and 4 in SS are depicted in Fig. 1a and b. Each patient
evaluation took <10min, and representative images were
archived. Inter-observer reliability was determined by comparing
the findings obtained by one of the rheumatologists experienced in
US (A.I.) and those of an experienced radiologist (M.C.) who
examined 48 parotid and submandibular glands in a random
subset of 12 patients. Each examiner performed the US assess-
ments independently and sequentially while blinded to all other
study data. Intra-observer reliability was assessed by blinded
rescoring of the archived US images in the same subset 2 months
after the original US assessment.
Sialographic evaluation
Conventional sialography was performed by using standard X-ray
equipment for skull imaging. Before contrast-enhanced images,
conventional radiographs were obtained in lateral projection to
detect grossly radiopaque sialoliths. Patients were in orthostatic
position, sat on a chair, with head in rest position and mildly
hyperextended. After identification of the orifice of the Stensen or
Wharton duct, the orifice was incannulated with a 24 Gauges
catheter [Gallini, Medical Devices, Mirandola (MO), Italy] or
with a Manashil catheter (COOK, Bjaeverskov, Denmark).
In patients whose ducts were difficult to identify, salivation was
stimulated by using a lemon mouth swab (especially for cannu-
lation of the Wharton duct). Conventional films were obtained
after manual injection of 0.5–2ml of non-ionic contrast medium
(Iopamiro 300mgI/ml, Bracco, Milano, Italy). The sialographic
patterns obtained were classified in different stages, determined on
FIG. 1. Sonography of a parotid gland in patients with pSS. (a) Gland with irregular echogenicity and multiple hyperechoic bands and hypoechoic areas (grade 3);
(b) gland with irregular contour, multiple large hypoechoic areas and multiple cysts (>6 mm) resulting in severe damage of the parenchymal architecture (grade 4).
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the basis of lateral views, according to the criteria of Rubin and
Holt [16]: Stage 0¼ normal; Stage 1¼ punctuate, diffuse contrast
material collection 1mm in diameter; Stage 2¼ globular,
contrast material collection 1–2mm in diameter (Fig. 2);
Stage 3¼ cavitary, contrast material collection >2mm in diam-
eter; Stage 4¼ destructive [16].
Scintigraphic measurements
Patients were injected intravenously with 110 MBq technetium
pertechnetate (99mTc) and images were obtained immediately after
injection to follow the accumulation phase. The patient lay supine
and the camera was positioned frontally. A dynamic study of
40–45min with 30 s per frame was carried out. Stimulation with
citric acid was performed 25min later, after which the secretory
phase was followed for over 20–25min. Salivary gland scinti-
graphic data were gathered with a gammacamera with a low-
energy general purpose collimator. In the dynamic image sets, the
four major salivary glands (submandibular and parotid glands)
were followed and the mouth and a background region on the
brain were outlined to generate background curves for subtrac-
tion. The scintigraphic stages were determined according to the
criteria proposed by Schall et al. [17] and Daniels et al. [18]. The
criteria comprised five stages: Stage 0 (normal)—rapid uptake,
progressive increase in concentration and prompt excretion into
the oral cavity within the first 10min; Stage 1 (mild)—relatively
normal salivary dynamics but a delay in the entire time sequence
and absence of excretion into the oral cavity by 10min; Stage 2
(moderate)—decreased uptake and concentration and absence
of excretion into the oral cavity by 20min; Stage 3 (severe)—
markedly decreased uptake and concentration and absence of
excretion into the oral cavity by 60min; Stage 4 (very severe)—
complete absence of active concentration and the oral cavity may
even appear as a negative defect at 60min. Decreased uptake and
concentration and delayed excretion on salivary gland scintigra-
phy (Stage 1 or more) were considered abnormal.
Statistical analysis
Data were submitted for statistical analysis using MedCalc
(version 9.3 for Windows XP) in order to calculate receiver
operating characteristic (ROC) curves, and the Statistical Package
for the Social Sciences (SPSS) version 11.0 was used for the
remaining statistical procedures. Parametric techniques may be
applicable for certain ordinal level data; however, our data was
generally not normally distributed (Kolmogorov–Smirnov test for
normal distribution), and therefore, the use of non-parametric
techniques provided a more conservative estimate of statistical
significance. Where appropriate, median and interquartile ranges
are given, as well as mean and S.D. The differences among
the groups were computed by the Mann–Whitney U-test and
Kruskal–Wallis one way analysis of variance for continuous
variables or ordinal scaled scores and Fisher’s exact test for
categorical variables. Inter-observer reliability was determined by
the unweighted -statistics. Discriminant validity was assessed
by ROC curve analysis to compare the ability of US to discrimi-
nate between pSS and control patients, in comparison with con-
ventional contrast sialography and scintigraphy of the salivary
glands. ROC curves were plotted for each model to determine the
area under the curve (AUC) and the sensitivity (probability that
a test result will be positive when the pSS is present), specificity
(probability that a test result will be negative when the pSS is not
present) and positive likelihood ratio (LR) [19]. The LR combines
information about the sensitivity and specificity. An LR expresses
the addition that a given level of a diagnostic tests results would
be expected in a patient with (as opposed to someone without) the
target disorder. The AUC was used to evaluate the diagnostic
performance of the test. The non-parametric Wilcoxon’s signed-
rank test was used for calculation and comparison of the areas
under the ROC curves (AUC-ROCs) derived from the sample of
patients, as suggested by Hanley and McNeil [20].
Results
Patients
Using the AECG classification criteria for SS [3], 77 patients were
classified as pSS (male/female ratio 3/74; mean age 54 yrs, S.D.
12.1, range 30–78 yrs) and 79 patients as negative for pSS (male/
female ratio 6/73; mean age 53 yrs, S.D. 12.3, range 24–81 yrs).
This control group complained of dry mouth due to other
diseases, such as diabetes mellitus (n¼ 14), fibromyalgia (n¼ 19),
hyperlipidaemic states (n¼ 10), chronic liver diseases (n¼ 8),
hypothyroidism (n¼ 5) and anxiety and/or depression (n¼ 14).
In the other nine patients in whom pSS was excluded, histo-
pathological findings showed no inflammatory infiltrate (grade 0
or 1); therefore, the cause of xerostomia in these patients remained
undiagnosed. Therefore, none of them fulfilled the aforemen-
tioned AECG criteria for the diagnosis of pSS [3]. The mean
duration of subjective xerostomia in the pSS patients was 2.9 yrs
(range 6 months–10 yrs), which was similar to that of the controls
(mean 2.8 yrs, range 4 months–12 yrs). In addition, there was no
statistically significant difference between these two groups in the
use of anti-cholinergic drugs, and smoking. On the other hand,
the difference between the pSS and symptomatic controls was
statistically significant for objective features of dry eyes
(P¼ 0.003) and dry mouth (P< 0.001) and for presence of anti-
Ro/SSA and/or anti-La/SSB. Forty of the 77 patients (51.9%)
with pSS were anti-Ro/SSA and/or anti-La/SSB positive, 31/77
were ANA positive (40.3%), 29/77 were FR positive (37.7%) and
none of the patients with sicca symptoms but without pSS were
anti-Ro/SSA or anti-La/SSB positive. Focal sialadenitis was
observed in 69/77 patients (89.6%) with pSS.
Inter- and intra-observer agreement in imaging assessment
The reliability of imaging techniques was assessed in 12 pSS
patients. The inter-observer reliability showed an overall agree-
ment of 89, 82 and 78% for the presence/absence of parenchymal
homogeneity, echogenicity, size of the glands and posterior glan-
dular border, with k-values of 0.832, 0.791 and 0.715, respectively.
The intra-observer reliability US assessment showed an overall
agreement of 91, 88 and 85%, with k-values of 0.852, 0.821 and
0.804%, respectively. The inter-observer agreements in staging of
FIG. 2. Sialography of a parotid gland in lateral view shows chraracteristic globular
pattern of sialectasia in a patient with pSS.
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disease on contrast sialography and salivary gland scintigraphy
were excellent, with k-values of 0.791 and 0.843, respectively.
US compared with contrast sialography and parotid
gland scintigraphy
Among the 77 patients with pSS, 66 (85.7%) had abnormal US
findings (score 1 in both parotids or both submandibular
glands). The findings of parotid and submandibular glands were
in concordance with each other and were equally frequent. The
US score was calculated by summing the grades obtained by
the evaluation of all four glands and based on the assessment of
the five observed parameters. The mean US score in pSS patients
was 9.0 (range from 3 to 16). Subjects without confirmed pSS had
a mean US score of 3.9 (range from 0 to 9; P< 0.0001). From the
results of the contrast sialography, 59 pSS patients had abnormal
findings of Stage 1 (punctate; n¼ 4), Stage 2 (globular; n¼ 8),
Stage 3 (cavitary; n¼ 33) or Stage 4 (destructive; n¼ 14). Fifty-
eight pSS patients had abnormal scintigraphic findings of Stage 1
(mild; n¼ 11), Stage 2 (moderate; n¼ 18), Stage 3 (severe; n¼ 25)
or Stage 4 (very severe; n¼ 4). The scores of parotid glands on
contrast sialography and scintigraphy were closely related to
each other (2¼ 65.53, P< 0.0001). A true-positive result on US,
contrast sialography and salivary gland scintigraphy was seen in
46 pSS patients. A false-negative result for all three imaging
methods was present in three patients. Of the 79 patients in whom
the pSS was excluded, 21 false-positive cases were seen on US,
19 cases on contrast sialography and 33 cases on scintigraphy.
Diagnostic accuracy of imaging diagnostic tests
ROC curves were constructed by computing the sensitivity and
specificity of different tests and their accuracy was measured by
the AUC-ROC. The calculated contrast sialography AUC-ROC
(0.804 0.035; 95% CI 0.733, 0.864) was intermediate between the
salivary gland US AUC-ROC curve (0.863 0.030; 95% CI 0.799,
0.913) (differences between areas¼ 0.059 0.039; 95% CI –0.017,
0.134; P¼ 0.129) and the AUC of the salivary gland scintigraphy
ROC curve (0.783 0.037; 95% CI 0.710, 0.845) (differences
between areas¼ 0.021 0.044; 95% CI –0.065, 0.108; P¼ 0.629).
The difference between the US AUC-ROC and salivary gland
scintigraphy ROC curve was significant (differences between
areas¼ 0.080 0.038; 95% CI 0.006, 0.154; P¼ 0.034), reflecting
the accuracy of the US diagnostic assessment. Our findings are
represented in Fig. 3. From the ROC curves we computed the
optimal cut-off points, corresponding with the maximum sum of
sensitivity and specificity. These theoretically optimal upper limits
of reference values and corresponding values of positive likelihood
ratio are shown in Tables 1–3. For the US score (on a scale of
0–16) and optimal cut-off point >6 comes close to maximizing
both sensitivity and specificity. With this optimal cut-off point,
sensitivity was 75.3% and specificity was 83.5% (LR 4.58). If a
threshold >8.0 was applied the test gained specificity, at the cost
of a serious loss of sensitivity (sensitivity 54.5%, specificity 97.5%,
likelihood ratio 21.5; Table 1). For the contrast sialography
and salivary gland scintigraphy at threshold >1, sensitivity were
72.7 and 70.1%, and specificity were 84.9 and 82.3%, respectively
(Tables 2 and 3).
Discussion
Salivary gland involvement in SS is usually evaluated by contrast
sialography or labial gland biopsy [3]. Although these two proce-
dures are believed to be the most sensitive and specific diagnostic
approaches, their usefulness as a screening test is hampered by
their invasive nature [21, 22]. The sensitivity of contrast sialo-
graphy has ranged from 66% to 95% in different studies [23–25],
while diagnostic specificity of parotid sialographic changes in SS
is affected by two lines of evidence. First, the sialographic pat-
terns associated with SS are also seen in glands with chronic
FIG. 3. ROC curves for the performance of the salivary gland US, contrast sialo-
graphy and scintigraphy in discriminating between pSS and symptomatic controls.
TABLE 1. Sensitivity, specificity (with 95% CI) and positive LR of salivary gland US
score
Criterion Sensitivity 95% CI Specificity 95% CI þLR
0 100.00 95.3, 100.0 0.00 0.0, 4.6 1.00
>0 100.00 95.3, 100.0 21.52 13.1, 32.2 1.27
>1 100.00 95.3, 100.0 22.78 14.1, 33.6 1.30
>2 100.00 95.3, 100.0 30.38 20.5, 41.8 1.44
>3 90.91 82.2, 96.3 36.71 26.1, 48.3 1.44
>4 85.71 75.9, 92.6 49.37 37.9, 60.9 1.69
>5 83.12 72.9, 90.7 73.42 62.3, 82.7 3.13
>6a 75.32 64.2, 84.4 83.54 73.5, 90.9 4.58
>7 72.73 61.4, 82.3 86.08 76.4, 92.8 5.22
>8 54.55 42.8, 65.9 97.47 91.1, 99.6 21.55
>9 44.16 32.8, 55.9 100.00 95.4, 100.0
>10 42.86 31.6, 54.6 100.00 95.4, 100.0
>11 20.78 12.4, 31.5 100.00 95.4, 100.0
>12 12.99 6.4, 22.6 100.00 95.4, 100.0
>13 11.69 5.5, 21.0 100.00 95.4, 100.0
>14 5.19 1.5, 12.8 100.00 95.4, 100.0
>15 2.60 0.4, 9.1 100.00 95.4, 100.0
>16 0.00 0.0, 4.7 100.00 95.4, 100.0
AUC-ROC¼ 0.863, S.E.¼ 0.030, 95% CI 0.799, 0.913. aOptimal cut-off point.
TABLE 2. Sensitivity, specificity (with 95% CI) and positive LR of salivary gland
sialography
Criterion Sensitivity 95% CI Specificity 95% CI þLR
0 100.00 95.3, 100.0 0.00 0.0, 4.6 1.00
>0 74.03 62.8, 83.4 74.68 63.6, 83.8 2.92
>1a 72.73 61.4, 82.3 84.87 80.0, 91.5 7.18
>2 61.04 49.2, 72.0 92.41 84.2, 97.1 8.04
>3 18.18 10.3, 28.6 98.73 93.1, 99.8 14.36
>4 0.00 0.0, 4.7 100.00 95.4, 100.0
AUC-ROC¼ 0.804, S.E.¼ 0.035, 95% CI 0.733, 0.864. aOptimal cut-off point.
TABLE 3. Sensitivity, specificity (with 95% CI), and positive LR of salivary gland
scintigraphy
Criterion Sensitivity 95% CI Specificity 95% CI þLR
0 100.00 95.3, 100.0 0.00 0.0, 4.6 1.00
>0 84.42 74.4, 91.7 41.77 30.8, 53.4 1.45
>1a 70.13 58.6, 80.0 82.28 72.1, 90.0 3.96
>2 37.66 26.9, 49.4 97.47 91.1, 99.6 14.88
>3 5.19 1.5, 12.8 98.73 93.1, 99.8 4.10
>4 0.00 0.0, 4.7 100.00 95.4, 100.0
AUC-ROC¼ 0.783, S.E.¼ 0.037, 95% CI 0.710, 0.845. aOptimal cut-off point.
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inflammation that is not associated with SS, in recurrent parotitis
of childhood [26], and in lympho-epithelial lesions not associated
with SS [27]. Second, the results from some studies demonstrate
abnormal parotid sialographic findings in control subjects with
supposedly normal parotid glands. In two such studies, abnormal
sialograms were observed in 15% [5] and 39% [28] of control
subjects, which would translate into specificity values of 85 and
61%, respectively. On the other hand, the scintigraphic method
with 99mTc pertechnetate is a non-invasive technique and has been
used to evaluate the salivary gland function in patients with SS
[17, 29]. Sensitivity of scintigraphy has been 73–80% [17, 29], and
specificity quite poor in several studies [30–32]. The low specificity
of salivary gland scintigraphy may be derived from the fact that
decreased uptake and delayed excretion of 99mTc pertechnetate is
a non-specific phenomenon, not to be considered pathognomonic
for SS [17]. Bilaterally decreased uptake and delayed excretion
may be seen in patients with other systemic CTDs, chronic recur-
rent sialodochoadenitis, sialadenosis and physiological ageing as
well as in those with SS [17]. Although quantitative scintigraphic
studies with computer-assisted analysis of the regions of interest
have been attempted, there is still controversy about the optimal
method for assessing SS [29, 33]. The original European classi-
fication criteria for SS [32] have been criticized, because their use
may lead to over-diagnosis. If four of the six classification criteria
are met, the specificity and sensitivity of the SS diagnosis should
be quite high, 95%. However, if these four items are subjective
feelings of dry eyes and dry mouth associated with diminished
lachrymal and salivary flow, then patients with neural dysregula-
tion of the exocrine glands might become false positives [34].
Therefore, in the revised AECG criteria [3], autoantibodies and/or
focal sialadenitis are required for a diagnosis of SS. The present
study suggests that in combination with a laboratory test for anti-
Ro/SSA and anti-La/SSB antibody positivity, US of the major
salivary glands also can be useful in the differentiation between
patients with pSS and patients with sicca symptoms but without
SS. Previously, it has been suggested that US evaluation of the
salivary glands is useful in the diagnosis of SS [13]. Kawamura
et al. [11] and, more recently, Ariji et al. [12] showed that descrip-
tive and quantitative assessment of the salivary glands by US
efficiently differentiated between diseased and normal glands in
patients with SS. They showed that the proposed sonographic
gradings correlated well with the sialographic gradings [11, 12].
In the present study, the sensitivity of US imaging at the cut-off
point >6 was slightly higher than that of contrast sialography and
salivary gland scintigraphy (75.3, 72.7 and 70.1%, respectively),
whereas the specificity was quite similar (83.5, 84.9 and 82.3%,
respectively). These percentages are within the otherwise wide
range of previous studies showing a sensitivity of US between
43% and 90% and a specificity between 83.3% and 100% [11, 12,
35–39]. For this threshold value of >6 in scoring system, the
positive LR of an abnormal US was 4.58. For clinicians, the
positive LR is the most important measure of a test’s perfor-
mance. The likelihood that a given test result would be expected in
a patient with the target disorder compared with the likelihood
that the same result would be expected in a patient without the
target disorder. If a cut-off point >8.0 was applied, the US scoring
system gained specificity, but at the cost of a loss of sensitivity
(sensitivity 54.5%, specificity 97.5%, LR 21.5). This high level
of LR suggests that the US changes described are sufficiently
diagnostic of SS, and therefore, it may be unnecessary to perform
contrast sialography or salivary gland scintigraphy on a patient
with high anti-Ro and/or anti-La antibody titres. According to
our sonographic scoring system [13] the grade 2 corresponds an
evident parenchymal inhomogeneity, characterized by multiple
scattered hypoechogenic areas usually of variable size (<2mm)
and not uniformly distributed. In fact, it is accepted by the
majority of authors [35–39] that the most relevant sonographic
sign in SS is parenchymal inhomogeneity, which is considered the
most gland important structural change in these patients, and is
determined in comparison with that of the thyroid gland [36, 39].
However, only evident inhomogeneity, characterized by multiple
scattered hypoechoic areolae to multiple cyst-like changes in the
gland parenchyma, can be regarded as being of true diagnostic
value for the disease, because mild inhomogeneity may also be
present in other disorders with subjective xerostomia. In the dif-
ferential diagnosis of SS, many conditions can cause an inhomo-
geneity and hypoechogenicity in the parenchymal of the salivary
glands, such as acute bacterial infection, but in this case the
structural change is often unilateral. Also abscesses, haematoma
and neoplasm are predominantly unilateral. On the contrary, in
SS this structural change is, in most cases, bilateral and equally
frequent in parotid and submandibular glands [37]. On the other
hand, viral infections, chronic parotitis or sarcoidosis, limited only
in the parotid glands, can mimic SS parotids, because they can
produce similar changes [38]. In our study, which also included
patients with sicca syndrome, we observed parenchymal inhomo-
geneity with hypoechogenic area within the parotid and sub-
mandibular glands; however, advance structural changes were
more commonly found in SS patients than in patients with sicca
symptoms, not fulfilling the criteria for definite SS. We employed
the ROC curves to describe how well US examination can
distinguish SS patients from those with sicca syndrome. A positive
US result was the best performer, followed by salivary gland
sialography and scintigraphy. The AUC-ROC in all of these three
imaging investigations reached the range of good accuracy.
In conclusion, our experience leads us to believe that salivary
gland US is an useful method in visualizing glandular structural
changes in patients suspected of having SS and it may represent
a good candidate for a first-line imaging tool in the diagnostic
setting of the disease as well as a monitoring possibility during the
follow-up of SS patients. For this reason, we suggest taking into
consideration the introduction of salivary gland US as an alter-
native structural method to sialography and, in our opinion it
would be of interest to complete the classification criteria for SS
established by the AECG by this non-invasive imaging procedure,
as proposed by other examiners [38–40].
Disclosure statement: The authors have declared no conflicts of
interest.
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